Study summary

Adding lenvatinib to chemotherapy delayed growth but not death

Lenvatinib OLIE trial · 81 people aged 2 to 25, phase 2, randomized · Published December 2024, JAMA Oncology

What was tested

Lenvatinib added to ifosfamide and etoposide against chemotherapy alone in children and young adults with relapsed osteosarcoma.

What they found

• Time before growth improved (hazard ratio 0.54), though the medians were close.
• Overall survival was not better.
• Serious side effects were common in both groups.

What it means

Shows that delaying growth does not always mean longer life in relapsed osteosarcoma.